Cue Biopharma appoints James Ahlers as Chief Financial Officer, effective July 30, 2026
Cue Biopharma's board appointed James Ahlers as Chief Financial Officer, effective July 30, 2026, and he will serve as the company's principal financial officer. Ahlers previously served as consulting CFO to life sciences companies and spent nearly two decades as CFO of Intarcia Therapeutics. The filing sets his annualized base salary at $450,000 and describes inducement equity grants and severance terms.
Key points
- Appointment effective July 30, 2026; Ahlers, age 62, will serve as principal financial officer.
- Annualized base salary of $450,000, with a discretionary annual bonus target of up to 45% of base salary.
- Initial option exercise price of $30.40, the Nasdaq closing price on the effective date; RSU award for 25,500 shares; grants vest quarterly over four years.
- Qualifying termination entitles him to a lump sum of nine months' base salary plus a prorated target bonus.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.